New hope for Hard-to-Treat breast cancer: drug combo trial launches

NCT ID NCT04468061

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding pembrolizumab to sacituzumab govitecan helps control metastatic triple-negative breast cancer that is PD-L1-negative. About 110 adults with advanced TNBC will be randomly assigned to receive either the combination or sacituzumab alone. The goal is to see if the combo slows cancer growth better than the single drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER PD-L1 NEGATIVE TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

DF/BWCC in Clinical Affiliation with South Shore Hospital
RECRUITING

South Weymouth, Massachusetts, 02190, United States
DFCI @ Foxborough
RECRUITING

Foxborough, Massachusetts, 02035, United States
DFCI @ Milford Regional Hospital
RECRUITING

Milford, Massachusetts, 01757, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Eastern Maine Medical Center
RECRUITING

Brewer, Maine, 04412, United States
Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States
Miami Cancer Institute at Baptist Health
RECRUITING

Plantation, Florida, 33324, United States
Miami Cancer Institute at Baptist Health (Kendall)
RECRUITING

Miami, Florida, 33176, United States
Ohio State University Medical Center
RECRUITING

Columbus, Ohio, 43212, United States
Sarah Cannon Research Institute
RECRUITING

Chattanooga, Tennessee, 37404, United States
Stamford Hospital
RECRUITING

Stamford, Connecticut, 06904, United States
The Christ Hospital Cancer Center
RECRUITING

Cincinnati, Ohio, 45219, United States
The University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Pennsylvania-Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.